Alterity surges after mid-stage trial data for lead asset
Alterity Therapeutics (NASDAQ:ATHA) announced Thursday that its lead candidate, ATH434, slowed clinical progression with a ...
Hosted on MSN14d
Alterity Therapeutics Advances ATH434 Clinical Trials with Promising Data
Alterity Therapeutics Ltd. ( ($AU:ATH) ) just unveiled an update. Alterity Therapeutics has completed its Phase 2 clinical trial of ATH434 in ...
Alterity Therapeutics announces ATH434 Phase 2 trial results
Alterity Therapeutics (ATHE) announced topline results from the ATH434-201 randomized, double-blind, placebo-controlled Phase 2 clinical trial ...
Biotech company Alterity Therapeutics seeking to raise $40m
MST Financial is managing the raise and has split it into two tranches. Shares were placed in a trading halt on Thursday.
Morningstar8d
Alterity Therapeutics Announces Positive ATH434 Phase 2 Trial Results in Multiple System Atrophy Led By Robust Clinical Efficacy
The topline data showed that ATH434 produced clinically and statistically significant improvement on the modified UMSARS Part I, a functional rating scale that assesses disability on activities ...